Treatment Options for Relapsed and Refractory Multiple Myeloma

被引：102

作者：

Lonial, Sagar ^{[1
]}

Mitsiades, Constantine S. ^{[2
]}

Richardson, Paul G. ^{[2
]}

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[2] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA

来源：

CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 06期

关键词：

PEGYLATED LIPOSOMAL DOXORUBICIN; STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; EXTENDED FOLLOW-UP; HISTONE-DEACETYLASE INHIBITORS; PHASE-II; ORAL CYCLOPHOSPHAMIDE; ANTITUMOR-ACTIVITY; PROGNOSTIC-FACTORS; VAD CHEMOTHERAPY;

D O I：

10.1158/1078-0432.CCR-10-1805

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment options for patients with relapsed myeloma have benefited from the development of new targeted agents. The use of bortezomib, thalidomide, and lenalidomide have dramatically changed outcomes for patients with relapsed myeloma. New agents are also in development, on the basis of preclinical rationale, as well as combinations of conventional and novel agents. Together each of these treatment approaches are being tested in phase I, II, and III clinical trials, with the goal of prolonged duration of remission and, ultimately, improved overall survival. Clin Cancer Res; 17(6); 1264-77. (C)2011 AACR.

引用

页码：1264 / 1277

页数：14

共 143 条

[1]

ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8

[2] Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfitzomib (PR-171) in hematologic malignancies [J].